Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A Key Pre-Distribution Scheme Based on ยต-PBIBD for Enhancing Resilience in Wireless Sensor Networks.

Yuan Q, Ma C, Yu H, Bian X.

Sensors (Basel). 2018 May 12;18(5). pii: E1539. doi: 10.3390/s18051539.

2.

Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.

Wang B, Xie H, Ma C, Zhang G, Gan H, Wang Q, Liu X, Zhu Y, Zhu Y, Shi G, Zhang H, Dai B, Shen Y, Ye D.

J Cancer. 2017 Sep 27;8(17):3490-3497. doi: 10.7150/jca.19109. eCollection 2017.

3.

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma.

Fangning W, Chunguang M, Hailiang Z, Guohai S, Yao Z, Bo D, Yijun S, Yiping Z, Dingwei Y.

J Cancer. 2017 Jul 5;8(11):2010-2017. doi: 10.7150/jca.18257. eCollection 2017.

4.

[Influence of clinical factors on Gleason score upgrade in patients undergoing radical prostatectomy].

Zhang G, Qin X, Han C, Gu C, Wan F, Qu Y, Gu W, Ma C, Zhu Y, Ye D.

Zhonghua Wai Ke Za Zhi. 2015 Jul 1;53(7):543-6. Chinese.

PMID:
26359080
5.

Downregulation of EphA5 by promoter methylation in human prostate cancer.

Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, Wu Z, Wang H, Xu X, Zhang H, Ren G, Tang J, Li X, Guan M.

BMC Cancer. 2015 Jan 22;15:18. doi: 10.1186/s12885-015-1025-3.

6.

Clinical significance of TMPRSS4 in prostate cancer.

Shi G, Yang X, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Xiao W, Ma C, Wen L, Qin X, Cao D, Ye D.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8053-8. eCollection 2014.

7.

GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.

Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, Shen X.

Anal Bioanal Chem. 2011 Aug;401(2):635-46. doi: 10.1007/s00216-011-5098-9. Epub 2011 May 29.

PMID:
21626193
8.

Extramammary Paget's diseases in men from the Shanghai area: its association with PSA level increase.

Shi G, Ye DW, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Xiao W, Ma C.

APMIS. 2010 Oct;118(10):777-81. doi: 10.1111/j.1600-0463.2010.02657.x.

9.

Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.

Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST.

J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):244-54. doi: 10.1016/j.jsbmb.2007.11.003. Epub 2008 Apr 20.

10.

Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.

Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST.

Mol Cancer Ther. 2006 Jul;5(7):1783-9.

12.

8-amino-adenosine is a potential therapeutic agent for multiple myeloma.

Krett NL, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V, Rosen ST.

Mol Cancer Ther. 2004 Nov;3(11):1411-20.

13.

In vitro assessment of nucleoside analogs in multiple myeloma.

Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V.

Cancer Chemother Pharmacol. 2004 Aug;54(2):113-21. Epub 2004 May 4.

PMID:
15133625
14.

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST.

Exp Hematol. 2003 Apr;31(4):271-82. Review.

PMID:
12691914

Supplemental Content

Loading ...
Support Center